Please login to the form below
IFM Tre
This page shows the latest IFM Tre news and features for those working in and with pharma, biotech and healthcare.
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
IFM Tre isn’t the only company working on inflammasomes, or indeed NLRP3. ... IFM Tre has only been in existence a few months, coalescing from assets that were left over when Bristol-Myers Squibb acquired IFM Therapeutics for $2.3bn in 2017.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- AstraZeneca officially opens new R&D facility in UK
- Biogen hands out $120m upfront for Remedy stroke drug
- China backs use of Roche’s Actemra for coronavirus
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
